Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

Ding, Kaibo; Peng, Zhongsheng; Liu, Dujiang; Xu, Yanjun

Ding, Kaibo; Peng, Zhongsheng; Liu, Dujiang; Xu, Yanjun.

Affiliation

Ding K; Department of Medical Thoracic Oncology, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, No. 1 East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Peng Z; Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China.
Liu D; Department of Medical Thoracic Oncology, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, No. 1 East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Xu Y; Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China.

J Transl Med ; 22(1): 761, 2024 Aug 14.

Article de En | MEDLINE | ID: mdl-39143613

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Acrylamides / Exons / Résistance aux médicaments antinéoplasiques / Récepteurs ErbB / Adénocarcinome pulmonaire / Afatinib / Dérivés de l'aniline / Tumeurs du poumon / Mutation Limites: Female / Humans / Male Langue: En Journal: J Transl Med Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google